Effects of chia seeds on psoriasis

Effects of CHIA SEED based nutraceutical products on PSORiatic plaques in a randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10951896

Enrollment

150

Registered

2017-02-22

Start date

2017-02-23

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic plaques Skin and Connective Tissue Diseases Psoriatic plaques

Interventions

Participants have photographs taken of their psoriasis lesions and the severity of their symptoms is measured. Participants undergo a clinical evaluation and fill out a questionnaire about dietary hab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women between 18-83 years of age 2. Caucasian 3. Chronic plaque psoriasis of any severity (treated and untreated)

Exclusion criteria

Exclusion criteria: 1. Smoking 2. Obesity (BMI >30 kg/m2) 3. Diabetes 4. Hepatic disease 5. Renal disease 6. Heart disease 7. Family history of chronic diseases 8. Heavy physical exercise (>10 h/week) 9. Pregnant women, women suspected of being pregnant, women who hoped to become pregnant, breastfeeding 10. Birch pollen allergy 11. Use of vitamin/mineral supplements 2 weeks prior to entry into the study 12. Donation of blood less than 3 months before the study

Design outcomes

Primary

Measure	Time frame
Size of erythema, desquamation and the size of the plaque being surveyed is measured using the Psoriasis Area Severity Index (PASI) at baseline, 4, 8, 12, and 16 weeks	—

Secondary

Measure	Time frame
1. Clinical history is measured both by interviews and previous clinical data at baseline 2. The reduction of itch is measured using Visual Analogue Scale (VAS) at baseline, 4, 8, 12, and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12, and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12, and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff baseline, 4, 8, 12, and 16 weeks 6. Blood analysis (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12, and 16 weeks	—

Measure

Time frame

1. Clinical history is measured both by interviews and previous clinical data at baseline 2. The reduction of itch is measured using Visual Analogue Scale (VAS) at baseline, 4, 8, 12, and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12, and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12, and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff baseline, 4, 8, 12, and 16 weeks 6. Blood analysis (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12, and 16 weeks

—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026